UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 17, 2008
BioMed Realty Trust, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Maryland
(State or other jurisdiction
of incorporation)
|
|
1-32261
(Commission File Number)
|
|
20-1142292
(I.R.S. Employer
Identification Number) |
17190 Bernardo Center Drive
San Diego, CA 92128
(Address of principal executive offices, including zip code)
(858) 485-9840
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On April 17, 2008, BioMed Realty Trust, Inc. (the “Company”) entered into an underwriting
agreement with Raymond James & Associates, Inc., as the representative of the underwriters (the
“Underwriters”), pursuant to which the Company agreed to issue and sell 5,700,000 shares of the
Company’s common stock, par value $0.01 per share (the “Common Stock”), plus up to an additional
855,000 shares of Common Stock pursuant to the Underwriters’ 30-day over-allotment option, at a
price to the public of $25.50 per share. The Underwriters exercised their over-allotment option
with respect to 429,000 shares on April 21, 2008. The offering closed on April 22, 2008. Gross
proceeds from the offering of an aggregate of 6,129,000 shares were approximately
$156.3 million. After the closing of the offering, the number of shares of Common Stock outstanding
was 71,722,285.
The Company intends to use the net proceeds of the offering to repay a portion of the
outstanding indebtedness under its $600.0 million unsecured line of credit and for other general
corporate and working capital purposes.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibits are filed herewith:
| |
|
|
| Exhibit |
|
|
| Number |
|
Description of Exhibit |
|
|
|
1.1
|
|
Underwriting Agreement, dated as of April 17, 2008, among the Company, BioMed Realty,
L.P. and Raymond James & Associates, Inc., as representative of the Underwriters |
|
|
|
5.1
|
|
Opinion of Venable LLP |
|
|
|
8.1
|
|
Opinion of Latham & Watkins LLP |
|
|
|
23.1
|
|
Consent of Venable LLP (contained in the opinion filed as Exhibit 5.1 hereto) |
|
|
|
23.2
|
|
Consent of Latham & Watkins LLP (contained in the opinion filed as Exhibit 8.1 hereto) |